Study guide

1.12 Pharmacology & Contrast Media in Radiation Therapy

ARRT Radiation Therapy Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Patient Care & Education

1.1 Patient Assessment, History, and Vital Signs 1.2 Psychosocial Support & Coping Mechanisms 1.3 Patient & Family Education on Radiation Therapy 1.4 Radiation Side Effect Management: Skin & Mucosal Reactions 1.5 Radiation Side Effect Management: Systemic & Organ-Specific Side Effects 1.6 Nutritional Support & Management of Dysphagia/Odynophagia 1.7 Medical Emergencies in Radiation Oncology 1.8 Patient Rights, Informed Consent, and Advanced Directives 1.9 Ethical, Legal, and HIPAA Considerations for Radiation Therapists 1.10 Infection Control & Sterile Technique in Radiation Therapy 1.11 Transfer & Positioning Safety for Oncology Patients 1.12 Pharmacology & Contrast Media in Radiation Therapy 1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation

2 Chapter 2: Radiation Physics, Radiobiology & Protection

2.1 Structure of Matter, Electromagnetic & Particulate Radiation 2.2 Radiation Production in Linear Accelerators & X-Ray Tubes 2.3 Photon & Electron Beam Interactions with Matter 2.4 Radiation Measurement Quantities, Units & Dosimeters 2.5 Radiation Protection Principles: ALARA, Time, Distance & Shielding 2.6 NCRP Dose Limits for Occupational & Public Exposure 2.7 Vault Design, Primary & Secondary Protective Barriers 2.8 Radiobiology Principles: Cell Survival Curves & Radiosensitivity (4 R's) 2.9 Linear Energy Transfer (LET) & Relative Biological Effectiveness (RBE) 2.10 Acute & Late Radiation Effects on Normal Tissues 2.11 Radiation Safety Rules, Emergency Procedures & Sealed Source Safety 2.12 MRI Magnetic Field Screening for Radiation Therapy Patients

3 Chapter 5: Treatment Sites, Tumors & Classification

5.1 Brain, Spinal Cord Tumors & Metastatic Patterns 5.2 Head & Neck Sites: Anatomy, Lymphatics & Patterns of Spread 5.3 Breast Cancer: Anatomy, Lymphatic Drainage & Radiation Considerations 5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures 5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns 5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites 5.7 Lymphoma, Sarcoma, Skin, Leukemia & Oncologic Emergencies 5.8 Tumor Classification: Histopathology, Grade & Staging Systems

4 Chapter 3: Treatment Planning & Dosimetry

3.1 CT Simulation, Patient Positioning & Target Localization 3.2 Immobilization Devices & Radiopaque Marking Protocols 3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR) 3.4 Beam Modifiers: Wedges, Compensators, Bolus & MLC Systems 3.5 Depth Dose Characteristics: PDD, TMR, TPR & TAR Relationships 3.6 Monitor Unit (MU) Calculations & Clinical Dosimetry Formulas 3.7 3D Conformal Radiation Therapy (3D-CRT) Beam Arrangements 3.8 IMRT, VMAT & Inverse Planning Optimization Concepts 3.9 SRS, SBRT & Stereotactic Radiosurgery Techniques 3.10 Brachytherapy Principles, HDR, LDR & Isotopes 3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances

5 Chapter 4: Treatment Delivery, Image Guidance & QA

4.1 Pre-Treatment Chart Check & Plan Verification Protocols 4.2 Daily Patient Positioning, Setup Tolerances & Alignment Verification 4.3 Image-Guided Radiation Therapy (IGRT): Portal Imaging & CBCT Verification 4.4 Linear Accelerator Safety Systems, Interlocks & Gantry Controls 4.5 Special Techniques: TBI, TSI, SGRT & Gated Radiotherapy 4.6 Daily Linac Quality Assurance per AAPM TG-142 Specifications 4.7 Monthly & Annual Linac QA Requirements & Dosimetric Calibration 4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification 4.9 Machine Malfunctions, Override Protocols & Emergency Off Procedures 4.10 Record and Verify (R&V) Systems, EHR Integration & Treatment Documentation

1.12 Pharmacology & Contrast Media in Radiation Therapy

Key Takeaways Explain This Topic AI

Non-ionic, low/iso-osmolar contrast has replaced older ionic, high-osmolar agents for IV use because it causes substantially fewer adverse reactions.

eGFR (calculated from creatinine, age, and sex) is the preferred renal-function screening value before contrast; metformin is typically held around contrast administration per protocol.

Extravasation presents as localized pain, swelling, and burning at the injection site; the injection must stop immediately and the physician be notified.

Contrast reactions range from mild (hives, flushing) to severe (laryngeal edema, shock) — severe reactions require immediate emergency activation while the therapist stays with the patient.

Hazardous drug and chemical handling (chemotherapy agents, disinfectants) is governed by Safety Data Sheets and USP <800>-aligned PPE and disposal practices.

Last updated: July 2026

Why Contrast Media Are Used in CT Simulation

Iodinated contrast media are administered during CT simulation to opacify blood vessels, highly vascular tumors, and certain organs (kidneys, bladder, GI tract), improving the physician's ability to distinguish tumor from adjacent normal structures and vasculature (e.g., separating a pancreatic head mass from the SMA/SMV, or a nodal mass from a great vessel) when contouring target volumes and organs at risk.

Ionic vs. Non-Ionic Contrast

Feature Ionic (older, high-osmolar) Non-ionic (newer, low/iso-osmolar)

Osmolality High — dissociates into charged particles in solution Lower — does not dissociate, fewer particles in solution

  • Adverse reaction rate Higher Lower
  • Cost Lower Higher
  • Current practice Largely phased out for IV use Standard for modern CT/IV contrast studies

Non-ionic, low-osmolar or iso-osmolar contrast is now the standard for intravenous use because it produces substantially fewer adverse reactions than older ionic, high-osmolar agents, even though it costs more per dose.

Renal Function Screening Before Contrast

Because iodinated contrast is cleared by the kidneys and can precipitate contrast-induced nephropathy (CIN) in patients with impaired renal function, departments screen renal function before administering IV contrast:

BUN (blood urea nitrogen) — reflects nitrogenous waste clearance; elevated in renal impairment but also affected by dehydration, diet, and other non-renal factors, so it is a less specific marker than creatinine.

Creatinine — a muscle-derived waste product cleared almost entirely by the kidneys; a more specific marker of renal function than BUN, though it is affected by muscle mass.

eGFR (estimated glomerular filtration rate) — calculated from creatinine, age, sex, and sometimes race; the preferred single value for screening because it estimates actual filtering capacity rather than relying on a raw lab value alone. Many departments set an eGFR threshold (commonly around 30 mL/min/1.73m², though institutional policy varies) below which contrast is avoided or requires nephrology consultation/hydration protocols.

Metformin — patients taking this diabetes medication are typically instructed to hold it around the time of contrast administration per institutional protocol, because impaired renal clearance of metformin in the rare setting of contrast-induced renal injury can precipitate lactic acidosis.

Extravasation

Extravasation occurs when contrast (or any IV medication) leaks from the vein into surrounding soft tissue during injection, most often at a power-injector site used for CT contrast boluses. Signs include localized swelling, pain, burning, and skin tightness/discoloration at the injection site during or immediately after injection. If the patient reports these symptoms during injection, the injection must be stopped immediately ; the therapist should notify the radiologist/physician, elevate the affected limb, apply cold or warm compresses per protocol, and document the incident, volume, and contrast type per department policy. Most extravasations are managed conservatively, but large-volume extravasations can require surgical consultation, particularly with high-osmolar agents that are more tissue-damaging.